Page 51 - 《南京医科大学学报》2026年第1期

第46卷第1期 卞雨蒙，丁紫藤，唐立钧，等. PET/MRI在乳腺癌诊疗方面的应用［J］.
2026年1月 南京医科大学学报（自然科学版），2026，46（1）：39-46 · 45 ·

MRI for detecting bone metastases in breast cancer：a me⁃ Cancers，2022，14（16）：3944
ta⁃analysis［J］. Radiol Oncol，2023，57（3）：299-309 ［31］JANNUSCH K，BITTNER A K，BRUCKMANN N M，et
［20］MELSAETHER A N，RAAD R A，PUJARA A C，et al. al. Correlation between imaging markers derived from
Comparison of whole⁃body（18）f fdg pet/mr imaging and PET/MRI and invasive acquired biomarkers in newly diag⁃
whole⁃body（18）f fdg pet/ct in terms of lesion detection nosed breast cancer［J］. Cancers，2023，15（6）：1651
and radiation dose in patients with breast cancer［J］. Ra⁃ ［32］HYDER T，BHATTACHARYA S，GADE K，et al. Ap⁃
diology，2016，281（1）：193-202 proaching neoadjuvant therapy in the management of early⁃
18
［21］HAN S，YOUNG C. Impact of F⁃FDG PET，PET/CT，and stage breast cancer［J］. Breast Cancer，2021，13：199-211
PET/MRI on staging and management as an initial staging ［33］SEKINE C，UCHIYAMA N，WATASE C，et al. Prelimi⁃
modality in breast cancer：a systematic review and meta⁃ nary experiences of PET/MRI in predicting complete re⁃
analysis［J］. Clin Nucl Med，2021，46（4）：271-282 sponse in patients with breast cancer treated with neoadju⁃
［22］CATALANO O A，DAYE D，SIGNORE A，et al. Staging vant chemotherapy［J］. Mol Clin Oncol，2022，16（2）：50
performance of whole⁃body DWI，PET/CT and PET/MRI ［34］DE MOOIJ C M，VAN NIJNATTEN T J A，GOORTS B，et
in invasive ductal carcinoma of the breast［J］. Int J Oncol， al. Prediction of primary tumour and axillary lymph node
2017，51（1）：281-288 response to neoadjuvant chemo（targeted）therapy with ded⁃
［23］RIGGIO A I，VARLEY K E，WELM A L. The lingering icated breast［18F］FDG PET/MRI in breast cancer［J］.
mysteries of metastatic recurrence in breast cancer［J］. Br Cancers，2023，15（2）：401
J Cancer，2021，124（1）：13-26 ［35］KOYASU H，GOSHIMA S，NODA Y，et al. The feasibility
［24］阳依宏，王海岩，祁 纳，等. F⁃FDG PET/MR在乳腺癌 of dedicated breast PET for the assessment of residual tu⁃
18
分期及复发检测中的临床应用研究［J］. 中国临床医学 mor after neoadjuvant chemotherapy［J］. Jpn J Radiol，
影像杂志，2021，32（12）：853-856 2019，37（1）：81-87
YANG Y H，WANG H Y，QI N，et al. Clinical application ［36］陈锦泉，丁紫藤，唐立钧，等. 乳腺专用PET在乳腺癌中
18
of F⁃FDG PET/MR in breast cancer staging and recur⁃ 的临床应用进展［J］. 南京医科大学学报（自然科学
rence detecting［J］. J Chin Clin Med Imaging，2021，32 版），2024，44（5）：726-731
（12）：853-856 CHEN J Q，DING Z T，TANG L J，et al. Advances in the
［25］GRUENEISEN J，SAWICKI L M，WETTER A，et al. Eval⁃ clinical application of dedicated breast PET in breast can⁃
18
uation of PET and MR datasets in integrated F ⁃ FDG cer［J］. Journal of Nanjing Medical University（Natural
PET/MRI：a comparison of different MR sequences for Sciences），2024，44（5）：726-731
whole⁃body restaging of breast cancer patients［J］. Eur J ［37］KITAJIMA K，YAMANO T，FUKUSHIMA K，et al. Corre⁃
Radiol，2017，89：14-19 lation of the SUVmax of FDG⁃PET and ADC values of dif⁃
［26］SAWICKI L M，GRUENEISEN J，SCHAARSCHMIDT B fusion ⁃ weighted MR imaging with pathologic prognostic
M，et al. Evaluation of F⁃fdg pet/mri，F⁃fdg pet/ct，mri， factors in breast carcinoma［J］. Eur J Radiol，2016，85
18
18
and ct in whole⁃body staging of recurrent breast cancer［J］. （5）：943-949
Eur J Radiol，2016，85（2）：459-465 ［38］GELEZHE P B，BLOKHIN I A，MARAPOV D I，et al.
［27］XIONG X，ZHENG L W，DING Y，et al. Breast cancer： Quantitative parameters of MRI and（18）F⁃FDG PET/CT
pathogenesis and treatments［J］. Signal Transduct Target in the prediction of breast cancer prognosis and molecular
Ther，2025，10（1）：49 type：an original study［J］. Am J Nucl Med Mol Imaging，
［28］UMUTLU L，KIRCHNER J，BRUCKMANN N M，et al. 2020，10（6）：279-292
Multiparametric integrated（18）F⁃FDG PET/MRI⁃based ［39］HUANG S Y，FRANC B L，HARNISH R J，et al. Explora⁃
radiomics for breast cancer phenotyping and tumor decod⁃ tion of PET and MRI radiomic features for decoding
ing［J］. Cancers，2021，13（12）：2928 breast cancer phenotypes and prognosis［J］. NPJ Breast
［29］CATALANO O A，HORN G L，SIGNORE A，et al. PET/ Cancer，2018，4：24
MR in invasive ductal breast cancer：correlation between ［40］MURAKAMI W，TOZAKI M，SASAKI M，et al. Correla⁃
imaging markers and histological phenotype［J］. Br J Can⁃ tion between（18）F⁃FDG uptake on PET/MRI and the lev⁃
cer，2017，116（7）：893-902 el of tumor⁃infiltrating lymphocytes（TILs）in triple⁃nega⁃
［30］ROMEO V，KAPETAS P，CLAUSER P，et al. A simulta⁃ tive and HER2⁃positive breast cancer［J］. Eur J Radiol，
neous multiparametric（18）F ⁃ FDG PET/MRI radiomics 2020，123：108773
model for the diagnosis of triple negative breast cancer［J］. ［41］DONG Y，HOU H F，WANG C Y，et al. The diagnostic